Prognostic assessment of apoptotic gene polymorphisms in non-small cell lung cancer in Chinese

Journal of Biomedical Research

Volumn 27, Issue 3, 2013, Pages 231-238

  Cao, Songyu ^a   Wang, Cheng ^a   Huang, Xinen ^b   Dai, Juncheng ^a   Hu, Lingmin ^a   Liu, Yao ^a   Chen, Jiaping ^a   Ma, Hongxia ^a   Jin, Guangfu ^a,c   Hu, Zhibin ^a,c   Xu, Lin ^b   Shen, Hongbing ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c Prevention and Treatment   (China)

Author keywords

Apoptosis; Non small cell lung cancer (NSCLC); Polymorphisms; Prognosis

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; FAS ANTIGEN; FAS LIGAND; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN MCL 1;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; CLINICAL FEATURE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84915798179     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.27.20130014     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83:584-94.
4. Cotter TG. Apoptosis and cancer: the genesis of a re-search field. Nat Rev Cancer 2009; 9: 501-7.
5. Vermeulen K, Van Bockstaele DR, Berneman ZN. Ap-optosis: mechanisms and relevance in cancer. Ann He-matol 2005; 84: 627-39.
6. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-95.
7. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005; 11: 3974-86.
8. Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, et al. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007; 109: 290-7.
9. Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, et al. The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res 2007; 13: 5790-7.
10. Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, et al. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol 2009; 20: 1094-9.
11. Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, et al. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. Leuk Res 2010; 34: 166-72.
12. Sreeja L, Syamala V, Raveendran PB, Santhi S, Madha-van J, Ankathil R. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian popu-lation. Cancer Invest 2008; 26: 41-6.
13. Guan X, Liao Z, Ma H, Qian J, Liu Z, Yuan X, et al. TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 2011; 11: 447.
14. Park JY, Lee WK, Jung DK, Choi JE, Park TI, Lee EB, et al. Polymorphisms in the FAS and FASL genes and survival of early-stage non-small-cell lung cancer. Clin Cancer Res 2009; 15: 1794-800.
15. Yoo SS, Choi JE, Lee WK, Choi YY, Kam S, Kim MJ, et al. Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. J Clin Oncol 2009; 27: 5823-9.
16. Lee EB, Jeon HS, Yoo SS, Choi YY, Kang HG, Cho S, et al. Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer. Ann Surg Oncol 2010; 17: 2608-18.
17. Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 2011; 12: 683-91.
18. Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 2006; 15: 1963-71.
19. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337-44.
20. Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin G, et al. A 3'-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010; 16: 1236-44.
21. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
22. Fukazawa T, Walter B, Owen-Schaub LB. Adenoviral Bid overexpression induces caspase-dependent cleavage of truncated Bid and p53-independent apoptosis in human non-small cell lung cancers. J Biol Chem 2003; 278: 25428-34.
23. Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E, et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009; 457: 1019-22.
24. Koomagi R, Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999; 84: 239-43.
25. Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 2000; 82: 1747-54.
26. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122: 1037-57.
27. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42